Therapeutic Asset Ratings
5,108 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Treosulfan
Myelodysplastic Syndrome
Masonic Cancer Center, University of Minnesota
P3
BB
(68)
Valganciclovir
Cytomegalovirus Infection
The Methodist Hospital Research Institute
P3
BB
(68)
Venetoclax
Disease Related To Hematopoietic Stem Cell Transplant
The First Affiliated Hospital of Soochow University
P3
BB
(68)
Venetoclax
Myeloid Neoplasm
First Affiliated Hospital of Zhejiang University
P3
BB
(68)
(+)-VINCRISTINE
Glioblastoma
University of Cincinnati
P3
BB
(68)
(+)-VINCRISTINE
Hodgkins Lymphoma
National Research Center for Hematology, Russia
P3
BB
(68)
(+)-VINCRISTINE
B-Cell Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
P3
BB
(68)
VINCRISTINE SULFATE
Adult Acute Lymphoblastic Leukemia
University of Washington
P3
BB
(68)
VINCRISTINE SULFATE
Splenic Marginal Zone Lymphoma
SWOG Cancer Research Network
P3
BB
(68)
Vinorelbine
Lung Adenocarcinoma
AIO-Studien-gGmbH
P3
BB
(68)
Vinorelbine
HER2 Positive Breast Carcinoma
Fudan University
P3
BB
(68)
Vinorelbine
Lung Cancer
Alliance for Clinical Trials in Oncology
P3
BB
(68)
Zanubrutinib
Splenic Marginal Zone Lymphoma
SWOG Cancer Research Network
P3
BB
(68)
Zorevunersen
Dravet Syndrome
Stoke Therapeutics, Inc
P3
BB
(68)
2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID
Primary Biliary Cholangitis
Intercept Pharmaceuticals
P3
BB
(67)
Acetylsalicylic Acid
Cerebrovascular Disorder
Peking Union Medical College Hospital
P3
BB
(67)
Alpelisib
Triple-Negative Breast Carcinoma
The Methodist Hospital Research Institute
P3
BB
(67)
ALTEPLASE
Basilar Artery Occlusion
The First Affiliated Hospital of University of Science and Technology of China
P3
BB
(67)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription
Thalassemia
Vertex Pharmaceuticals Incorporated
P3
BB
(67)
Avapritinib
Gastrointestinal Stromal Tumor
Blueprint Medicines Corporation
P3
BB
(67)
Azetukalner
Focal Epilepsy
Xenon Pharmaceuticals Inc.
P3
BB
(67)
BICALUTAMIDE
Triple-Negative Breast Carcinoma
Universitaire Ziekenhuizen KU Leuven
P3
BB
(67)
Blinatumomab
Childhood Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(67)
Blinatumomab
Adult Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(67)
Brentuximab Vedotin
Primary Cutaneous Anaplastic Large Cell Lymphoma
John Reneau
P3
BB
(67)
Showing 801 to 825 of 5,108 assets
Previous
Page 33 of 205
Next